诺和诺德(NVO.US)GLP-1赛道再下一城：Wegovy获FDA批准用于治疗肝病，近1500万美国患者适用

Core Insights - Novo Nordisk's weight loss drug Wegovy has received FDA approval for treating a serious liver disease, gaining a competitive edge over Eli Lilly [1] - The drug is indicated for adults with moderate to severe liver fibrosis associated with non-alcoholic steatohepatitis (NASH), a condition affecting approximately 6% of U.S. adults, or about 14.9 million people [1] - This approval allows Novo Nordisk to expand its market share in the growing GLP-1 drug market, amidst intense competition from lower-priced generics and Eli Lilly [1] Company Performance - Following the FDA approval, Novo Nordisk's stock rose by 7.14% in after-hours trading [2] - In contrast, Madrigal Pharmaceuticals, which is developing treatments for the same condition, saw a decline of approximately 7.53% [2] Clinical Efficacy - In a study, Wegovy improved liver fibrosis in 37% of patients without exacerbating inflammation, compared to only 22% improvement in the placebo group [2] - The proportion of patients experiencing relief from inflammation while taking Wegovy was nearly double that of those on placebo [2] - Novo Nordisk's Chief Scientific Officer highlighted that about one-third of overweight or obese individuals are affected by this liver condition, emphasizing Wegovy's role in preventing disease progression and aiding liver repair [2]